<p>This study combines RNA sequencing (RNASeq), whole exome sequencing (WES), reverse phase protein array (RPPA) and copy number variation (CNV) data, along with a custom high throughput inhibitor assay to characterize tumor cells from patients with head and neck squamous cell carcinoma (HNSCC), in order to identify potential therapy targets on an individual patient basis. The data that will be available through <a href="https://www.ncbi.nlm.nih.gov/gap/">dbGaP</a> include the RNASeq, WES, RPPA and array CNV data for the tumor and matched normal samples. This study represents a proof-of-concept. No treatments were administered to patients as part of this study. <br></p>

Assessing Individual Head and Neck Squamous Cell Carcinoma Patient    Response to Therapy Through Integration of Functional and Genomic Data

Squamous Cell Carcinoma of Head and Neck study with CNV Genotypes, Proteomics + 2 more data on dbGaP (20 participants)

phs003456 — Assessing Individual Head and Neck Squamous Cell Carcinoma Patient    Response to Therapy Through Integration of Functional and Genomic Data

Assessing Individual Head and Neck Squamous Cell Carcinoma Patient Response to Therapy Through Integration of Functional and Genomic Data

Description

Applying For Access

Summary